Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894543 · ClinicalTrials.gov registry record · NA
MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 205
- Enrollment target
NCT00894543 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 205 participants.
The verdict
NCT00894543, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro®) is a selective serotonin reuptake inhibitor (SSRI). It is sold by prescription for depression and general anxiety disorder. An SSRI increases serotonin, a brain substance that is believed to influence mood. Serotonin may also affect brain levels of estradiol, a hormone related to hot flashes. This research study will test whether escitalopram reduces menopausal hot flashes.
Interventions
- OTHER Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00894543
The ClinicalTrials.gov registry entry for NCT00894543 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00894543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00894543 about?
NCT00894543 is a clinical study titled "MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women". The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro®) is a selective serotonin reuptake inhibitor (SSRI). It is sold by prescription for depression and general anxiety disorder. An SSRI...
What is the current status of trial NCT00894543?
This trial is currently completed. It is a NA study. The enrollment target is 205 participants. The study started on 2009-07. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00894543?
The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00894543?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.